Taysha Gene Therapies, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 27th, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 27th, 2022 Company Industry JurisdictionTaysha Gene Therapies, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as the representative (the “Representative”), an aggregate of 14,000,000 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,100,000 additional shares (the “Optional Shares”) of common stock, par value $0.00001 per share (“Stock”), of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).